alexander perl, md, discusses abstract 7008 results and crenolanib potential activity
Published 8 years ago • 26 plays • Length 0:54
Download video MP4
Download video MP3
Similar videos
-
0:53
alexander perl, md, discusses the quantum first study and potential implications
-
1:23
alexander perl, md discusses cpx-351 (vyxeos) mechanism of action and why it is a promising agent
-
1:14
alexander perl, md, discusses the potential impact of potency when selecting a flt3 inhibitor
-
0:58
alexander perl, md, discusses the importance of sustained inhibition when selecting a flt3 inhibitor
-
0:59
alexander perl, md, discusses how molecular testing can facilitate decision making in aml patients
-
1:25
alexander perl, md, on importance of flt3 and provides his perspective on inhibitor differences
-
1:59
alexander perl, md, discusses treatment options for aml patients
-
0:32
alexander perl, md on treatment based on the phase iii study evaluating cpx-351 (vyxeos) versus 7 3
-
1:11:45
ippc 2023: novel perspectives on albumin use in cirrhosis
-
1:29:58
new perspectives on treating spinal stenosis with pild – evolving the treatment algorithm
-
39:05
liver pathology liver tumors updated 2022/23
-
1:18
alexander perl, md, on flt3 inhibitors in development and importance of hitting the flt3 target
-
1:17
alexander perl, md, on the role of immunotherapy in treating hematological malignancies
-
1:22
alexander perl, md, on aml trial results presented at this year’s ash meeting
-
1:40
alexander perl, md, discusses treatment options for patients with flt3-itd positive aml
-
1:23
eunice s. wang, md, on abstract 7008 & crenolanib potential activity in relapsed flt3 positive aml
-
9:39
alexander perl, md: the new flt3 inhibitor gilteritinib is “well-tolerated” in aml
-
2:10
alexander perl, md, on prognosis, diagnosis and treatment strategies for aml
-
0:41
alexander perl, md, on the toxicity in the phase 3 study evaluating cpx-351 (vyxeos)
-
1:01
alexander perl, md, on how the beat aml master trial will change the way aml patients are treated
-
7:36
alexander perl, eha 2019 – the phase iii admiral trial
-
4:04
dr. alexander perl, m.d., associate professor of medicine at the university of pennsylvania
Clip.africa.com - Privacy-policy